Concepedia

Safety and activity of tarlatamab in combination with a PD-L1 inhibitor as first-line maintenance therapy after chemo-immunotherapy in patients with extensive-stage small-cell lung cancer (DeLLphi-303): a multicentre, non-randomised, phase 1b study

Kelly G. Paulson, Sally C. M. Lau, Myung‐Ju Ahn, Mor Moskovitz, Michael Pogorzelski, Simon Häfliger, Amanda Parkes, Yuyang Zhang, Ali Hamidi, Corbin G. Thompson,

The Lancet Oncology · 2025 · 25 citations · 19 references

DOI

Concepts

References

19

First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer

Leora Horn, Aaron S. Mansfield, Aleksandra Szczęsna et al. · New England Journal of Medicine · 2018 · 3.5K citations · Full text

, , +17

Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial

Luis Paz‐Ares, Mikhail Dvorkin, Yuanbin Chen et al. · The Lancet · 2019 · 2.2K citations

, , +14

An Evolutionarily Conserved Function of Polycomb Silences the MHC Class I Antigen Presentation Pathway and Enables Immune Evasion in Cancer

Marian L. Burr, Christina E. Sparbier, Kah Lok Chan et al. · Cancer Cell · 2019 · 642 citations · Full text

, , +17

Identification of human cancers deficient in antigen processing.

Nicholas P. Restifo, Yutaka Kawakami, Jonathan W. Yewdell et al. · The Journal of Experimental Medicine · 1993 · 628 citations · Full text

, , +17

Tarlatamab for Patients with Previously Treated Small-Cell Lung Cancer

Myung‐Ju Ahn, Byoung Chul Cho, Enriqueta Felip et al. · New England Journal of Medicine · 2023 · 482 citations

, , +16